



利君國際醫藥(控股)有限公司

Lijun International Pharmaceutical (Holding) Co., Ltd.

(Incorporated in Cayman Islands with limited liability)

(Stock Code: 2005)

RE-DESIGNATION OF EXECUTIVE DIRECTOR, APPOINTMENT OF EXECUTIVE DIRECTORS AND APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR

The Board is pleased to announce that Mr. Qu Jiguang (formerly an independent non-executive Director of the Company) has been re-designated as an executive Director, the vice-chairman and the chief executive officer, Mr. Duan Wei, Mr. Wang Zhizhong, Ms. Zhang Guifu have been appointed as executive Directors and Mr. Wang Yibing has been appointed as an independent non-executive Director, member of the Audit Committee and member of the Remuneration Committee of the Company with effect from 26 July, 2007.

The Board of Directors (the “Board”) of Lijun International Pharmaceutical (Holding) Co., Ltd. (the “Company”) is pleased to announce that Mr. Qu Jiguang (formerly an independent non-executive Director of the Company) has been re-designated as an executive Director, vice-chairman and the chief executive officer, Mr. Duan Wei, Mr. Wang Zhizhong, Ms. Zhang Guifu have been appointed as executive Directors and Mr. Wang Yibing has been appointed as an independent non-executive Director, member of the Audit Committee and member of the Remuneration Committee of the Company with effect from 26 July, 2007. At the same time, Mr. Qu Jiguang has resigned as member of the Audit Committee and member of the Remuneration Committee.

The details of Mr. Qu Jiguang, Mr. Duan Wei, Mr. Wang Zhizhong, Ms. Zhang Guifu and Mr. Wang Yibing as required under Rule 13.51(2) of The Rules (the “Listing Rules”) Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “Stock Exchange”) are set out below.

Mr. Qu Jiguang (曲繼廣), aged 51, is an executive Director, the vice-chairman and the chief executive officer of the Company. Mr. Qu joined Shijiazhuang No.1 Pharmaceutical Factory (“No. 1 Pharma”) as deputy factory manager in 1995. He later became a director and the vice general manager of Shijiazhuang Pharmaceutical Group. From December 2004, Mr. Qu has been the chairman of New Orient Investments Limited, a wholly owned subsidiary of the Company (“New Orient”), the chairman and general manager of Shijiazhuang No. 4 Pharmaceutical Ltd, a wholly owned subsidiary of New Orient (“No. 4 Pharma”), the chairman of China Pharmaceutical Company Limited, which held 27.47% interest in the Company (“CPCL”) and the chairman of CMP Group Limited (“CMP”). Mr. Qu was an independent non-executive Director of the Company and was an executive director of China Pharmaceutical Group Limited, a company listed on the Stock Exchange, from February 2001 to September 2004. Mr. Qu graduated from Tianjin Finance College with a postgraduate degree in Finance in 1999. He is also an economist accredited by The Ministry of Personnel of China.

Mr. Qu has entered into a service contract with the Company for a fixed term of three years commencing from 17 October 2005 and with terms revised on 26 July 2007, subject to retirement and re-election provisions as set out in the Company's articles of association. Pursuant to the revised service contract, the annual director's emoluments of Mr. Qu is HK\$2,600,000 together with discretionary bonus based on the Company's performance. The terms of appointment were approved by the Remuneration Committee of the Company and the Board with reference to Mr. Qu's qualification and experience, responsibilities to be undertaken. In addition, Mr. Qu is eligible to participate in the Company's share option scheme.

On and since 29 June 2007, Mr. Qu was and has since then be deemed to be interested in 110,000,000 shares of the Company held by China Pharmaceutical Company Limited within the meaning of Part XV of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

Save as disclosed above, Mr. Qu does not have any relationships with any other directors, senior management or substantial shareholders (as defined in the Listing Rules), or controlling shareholders (as defined in the Listing Rules) of the Company.

Mr. Duan Wei (段偉), 48, is an executive Director. He joined No. 1 Pharma as a supervisor in March 1984 and was later promoted as the supervisor of Shijiazhuang Pharmaceutical Group. Mr. Duan has been an executive director and the vice general manager of No.4 Pharm since March 1999 and he has also been an executive director of New Orient, CPCL and CMP. Mr. Duan graduated from Hebei Central Radio and TV University (河北廣播電視大學) and has ample experiences in sales management.

Mr. Duan has entered into a service contract with the Company for a fixed term of three years commencing from 26 July 2007, subject to retirement and re-election provisions as set out in the Company's articles of association. Pursuant to the service contract, the annual director's emoluments of Mr. Duan is HK\$600,000 together with discretionary bonus based on the Company's performance. The terms of appointment were approved by the Remuneration Committee of the Company and the Board with reference to Mr. Duan's qualification and experience, responsibilities to be undertaken. In addition, Mr. Duan is eligible to participate in the Company's share option scheme. Save as disclosed above, Mr. Duan does not have any relationships with any other directors, senior management or substantial shareholders (as defined in the Listing Rules), or controlling shareholders (as defined in the Listing Rules) of the Company.

As at the date of this announcement, Mr. Duan was not interested or deemed to be interested in any shares or underlying shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

Mr. Wang Zhizhong (王志忠), 48, is an executive Director. He joined No.4 Pharm in September 1984 and later became an executive director and an assistant general manager. He has also been an executive director of New Orient, CPCL and CMP. Mr. Wang graduated with a bachelor degree from 瀋陽藥科大學 (Shenyang Pharmaceutical University) majoring in pharmacy research, production and human resources management.

Mr. Wang has entered into a service contract with the Company for a fixed term of three years commencing from 26 July 2007, subject to retirement and re-election provisions as set out in the Company's articles of association. Pursuant to the service contract, the annual director's emoluments of Mr. Wang is HK\$500,000 together with discretionary bonus based on the Company's performance. The terms of appointment were approved by the Remuneration Committee of the Company and the Board with reference to Mr. Wang's qualification and experience, responsibilities to be undertaken. In addition, Mr. Wang is eligible to participate in the Company's share option scheme. Save as disclosed above, Mr. Wang does not have any relationships with any other directors, senior management or substantial shareholders (as defined in the Listing Rules), or controlling shareholders (as defined in the Listing Rules) of the Company.

As at the date of this announcement, Mr. Wang was not interested or deemed to be interested in any shares or underlying shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

Ms. Zhang Guifu (張桂馥), 46, is an executive Director. Ms. Zhang joined Hebei Yuanzheng Pharmaceutical Company Limited (河北遠征藥業有限公司) as the finance manager in 1991. She has been the finance manager of No.4 Pharm since August 2001 and an executive director of No.4 Pharm since December 2001. She has also been an executive director of New Orient, CPCL and CMP. Ms. Zhang graduated from Hebei Economic Management College (河北經濟管理幹部學院) and has over 27 years of experience in financial control.

Ms. Zhang has entered into a service contract with the Company for a fixed term of three years commencing from 26 July 2007, subject to retirement and re-election provisions as set out in the Company's articles of association. Pursuant to the service contract, the annual director's emoluments of Ms. Zhang is HK\$300,000 together with discretionary bonus based on the Company's performance. The terms of appointment were approved by the Remuneration Committee of the Company and the Board with reference to Ms. Zhang's qualification and experience, responsibilities to be undertaken. In addition, Ms. Zhang is eligible to participate in the Company's share option scheme. Save as disclosed above, Ms. Zhang does not have any relationships with any other directors, senior management or substantial shareholders (as defined in the Listing Rules), or controlling shareholders (as defined in the Listing Rules) of the Company.

As at the date of this announcement, Ms. Zhang was not interested or deemed to be interested in any shares or underlying shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

Mr. Wang Yibing, aged 45, independent non-executive director. He graduated from Shenyang Pharmaceutical University, majored in pharmacy (沈陽藥科大學藥學). He is currently the executive vice-president of Hebei Province Pharmaceutical Industrial Chamber of Commerce (河北省醫藥行業協會). Mr Wang joined Hebei Provincial Pharmaceutical Research Centre (河北省藥物研究所) in July 1983 and became supervisor in research centre of pharmacodynamics, research centre of preparations, pharmaceutical factory and scientific research management centre successively. In 1991, Mr. Wang joined the General Economics Division of Hebei Provincial Administration of Medicine (河北省醫藥管理局綜合經濟處) as vice supervisor and was promoted to supervisor and the deputy director successively. From

April 2000 to July 2005, he was the Director of Division of Drug Registration and Division of Drug Safety and Inspection of Hebei Food and Drug Administration (河北省食品藥品監督管理局藥品注冊處，藥品安全監管處). Mr. Wang possesses about 24 years' experience in pharmaceutical research, production and industry regulation, is familiar with pharmaceutical laws and regulations and drug inspection procedures. He has profound exposure in the areas of pharmaceutical research, production, circulation and application, while comprehends and provides insights into the overall situation and trend of development of the pharmaceutical industry at both the provincial and state levels.

Mr. Wang has entered into a service contract with the Company for a fixed term of three years commencing from 26 July 2007, subject to retirement and re-election provisions as set out in the Company's articles of association. Pursuant to the service contract, the annual director's emoluments of Mr. Wang is HK\$180,000. The terms of appointment were approved by the Remuneration Committee of the Company and the Board with reference to Mr. Wang's qualification and experience, responsibilities to be undertaken. The Company had received from Mr. Wang a confirmation of his independence pursuant to Rule 3.13 of the Listing Rules and considered Mr. Wang to be independent.

As at the date of this announcement, Mr. Wang was not interested or deemed to be interested in any shares or underlying shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

Save as disclosed above, Mr. Wang does not have any relationships with any other directors, senior management or substantial shareholders (as defined in the Listing Rules), or controlling shareholders (as defined in the Listing Rules) of the Company.

For all of the above Directors, save as disclosed above, there is no information to be disclosed pursuant to any of the requirements under Rules 13.51(2)(a) to 13.51(2)(h) of the Listing Rules.

The Board would like to express its warm welcome to Mr. Qu Jiguang on his rejoining the Board as executive Director; and Mr. Duan Wei, Mr. Wang Zhizhong, Ms. Zhang Guifu and Mr. Wang Yibing on their joining the Board.

On behalf of the Board

Wu Qin

Chairman

Hong Kong, 27 July 2007

As at the date of this announcement, the Board comprises Wu Qin, Qu Jiguang, Wu Zhihong, Huang Chao, Xie Yunfeng, Sun Xinglai, Wang Xian Jun, Duan Wei, Wang Zhizhong and Zhang Guifu as executive Directors, Liu Zhiyong as non-executive Director and Wang Yibing, Leung Chong Shun and Chow Kwok Wai as independent non-executive Directors.